These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 36977840)
1. Routine imaging guided by a 31-gene expression profile assay results in earlier detection of melanoma with decreased metastatic tumor burden compared to patients without surveillance imaging studies. Dhillon S; Duarte-Bateman D; Fowler G; Hagstrom MNE; Lampley N; Olivares S; Fumero-Velázquez MS; Vu K; Wayne JD; Gastman BR; Vetto J; Gerami P Arch Dermatol Res; 2023 Oct; 315(8):2295-2302. PubMed ID: 36977840 [TBL] [Abstract][Full Text] [Related]
2. Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit. Grossman D; Okwundu N; Bartlett EK; Marchetti MA; Othus M; Coit DG; Hartman RI; Leachman SA; Berry EG; Korde L; Lee SJ; Bar-Eli M; Berwick M; Bowles T; Buchbinder EI; Burton EM; Chu EY; Curiel-Lewandrowski C; Curtis JA; Daud A; Deacon DC; Ferris LK; Gershenwald JE; Grossmann KF; Hu-Lieskovan S; Hyngstrom J; Jeter JM; Judson-Torres RL; Kendra KL; Kim CC; Kirkwood JM; Lawson DH; Leming PD; Long GV; Marghoob AA; Mehnert JM; Ming ME; Nelson KC; Polsky D; Scolyer RA; Smith EA; Sondak VK; Stark MS; Stein JA; Thompson JA; Thompson JF; Venna SS; Wei ML; Swetter SM JAMA Dermatol; 2020 Sep; 156(9):1004-1011. PubMed ID: 32725204 [TBL] [Abstract][Full Text] [Related]
3. Validation of a clinicopathological and gene expression profile model to identify patients with cutaneous melanoma where sentinel lymph node biopsy is unnecessary. Johansson I; Tempel D; Dwarkasing JT; Rentroia-Pacheco B; Mattsson J; Ny L; Olofsson Bagge R Eur J Surg Oncol; 2022 Feb; 48(2):320-325. PubMed ID: 34794843 [TBL] [Abstract][Full Text] [Related]
4. Performance of Gene Expression Profile Tests for Prognosis in Patients With Localized Cutaneous Melanoma: A Systematic Review and Meta-analysis. Marchetti MA; Coit DG; Dusza SW; Yu A; McLean L; Hu Y; Nanda JK; Matsoukas K; Mancebo SE; Bartlett EK JAMA Dermatol; 2020 Sep; 156(9):953-962. PubMed ID: 32745161 [TBL] [Abstract][Full Text] [Related]
5. Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients. Zager JS; Gastman BR; Leachman S; Gonzalez RC; Fleming MD; Ferris LK; Ho J; Miller AR; Cook RW; Covington KR; Meldi-Plasseraud K; Middlebrook B; Kaminester LH; Greisinger A; Estrada SI; Pariser DM; Cranmer LD; Messina JL; Vetto JT; Wayne JD; Delman KA; Lawson DH; Gerami P BMC Cancer; 2018 Feb; 18(1):130. PubMed ID: 29402264 [TBL] [Abstract][Full Text] [Related]
6. Expanded evidence that the 31-gene expression profile test provides clinical utility for melanoma management in a multicenter study. Dillon LD; McPhee M; Davidson RS; Quick AP; Martin B; Covington KR; Zolochevska O; Cook RW; Vetto JT; Jarell AD; Fleming MD Curr Med Res Opin; 2022 Aug; 38(8):1267-1274. PubMed ID: 35081854 [TBL] [Abstract][Full Text] [Related]
7. Utility of a 31-gene expression profile for predicting outcomes in patients with primary cutaneous melanoma referred for sentinel node biopsy. Arnot SP; Han G; Fortino J; Han D; Fowler G; Vetto JT Am J Surg; 2021 Jun; 221(6):1195-1199. PubMed ID: 33773750 [TBL] [Abstract][Full Text] [Related]
8. The 31-gene expression profile test informs sentinel lymph node biopsy decisions in patients with cutaneous melanoma: results of a prospective, multicenter study. Yamamoto M; Sickle-Santanello B; Beard T; Essner R; Martin B; Bailey CN; Guenther JM Curr Med Res Opin; 2023 Mar; 39(3):417-423. PubMed ID: 36617959 [TBL] [Abstract][Full Text] [Related]
9. Prospective validation of the prognostic 31-gene expression profiling test in primary cutaneous melanoma. Keller J; Schwartz TL; Lizalek JM; Chang ES; Patel AD; Hurley MY; Hsueh EC Cancer Med; 2019 May; 8(5):2205-2212. PubMed ID: 30950242 [TBL] [Abstract][Full Text] [Related]
10. Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma. Wagner JD; Ranieri J; Evdokimow DZ; Logan T; Chuang TY; Johnson CS; Jung SH; Wenck S; Coleman JJ Plast Reconstr Surg; 2003 Aug; 112(2):486-97. PubMed ID: 12900606 [TBL] [Abstract][Full Text] [Related]
11. Management Decisions Made by Physician Assistants and Nurse Practitioners in Cutaneous Malignant Melanoma Patients: Impact of a 31-Gene Expression Profile Test. Mirsky R; Prado G; Svoboda R; Glazer A; Rigel D J Drugs Dermatol; 2018 Nov; 17(11):1220-1223. PubMed ID: 30500144 [TBL] [Abstract][Full Text] [Related]
12. Validation of a clinicopathological and gene expression profile model for sentinel lymph node metastasis in primary cutaneous melanoma. Mulder EEAP; Dwarkasing JT; Tempel D; van der Spek A; Bosman L; Verver D; Mooyaart AL; van der Veldt AAM; Verhoef C; Nijsten TEC; Grunhagen DJ; Hollestein LM Br J Dermatol; 2021 May; 184(5):944-951. PubMed ID: 32844403 [TBL] [Abstract][Full Text] [Related]
13. Nodular Histologic Subtype and Ulceration are Tumor Factors Associated with High Risk of Recurrence in Sentinel Node-Negative Melanoma Patients. Faut M; Wevers KP; van Ginkel RJ; Diercks GF; Hoekstra HJ; Kruijff S; Been LB; van Leeuwen BL Ann Surg Oncol; 2017 Jan; 24(1):142-149. PubMed ID: 27646020 [TBL] [Abstract][Full Text] [Related]
14. Integration of a 31-Gene Expression Profile Into Clinical Decision-Making in the Treatment of Cutaneous Melanoma. Scott AM; Dale PS; Conforti A; Gibbs JN Am Surg; 2020 Nov; 86(11):1561-1564. PubMed ID: 32755379 [TBL] [Abstract][Full Text] [Related]
15. Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy. Gerami P; Cook RW; Russell MC; Wilkinson J; Amaria RN; Gonzalez R; Lyle S; Jackson GL; Greisinger AJ; Johnson CE; Oelschlager KM; Stone JF; Maetzold DJ; Ferris LK; Wayne JD; Cooper C; Obregon R; Delman KA; Lawson D J Am Acad Dermatol; 2015 May; 72(5):780-5.e3. PubMed ID: 25748297 [TBL] [Abstract][Full Text] [Related]
16. The 31-gene expression profile stratifies recurrence and metastasis risk in patients with cutaneous melanoma. Jarell A; Skenderis B; Dillon LD; Dillon K; Martin B; Quick AP; Siegel JJ; Rackley BB; Cook RW Future Oncol; 2021 Dec; 17(36):5023-5031. PubMed ID: 34587770 [TBL] [Abstract][Full Text] [Related]
17. Patterns of first-recurrence and post-recurrence survival in patients with primary cutaneous melanoma after sentinel lymph node biopsy. Dalal KM; Patel A; Brady MS; Jaques DP; Coit DG Ann Surg Oncol; 2007 Jun; 14(6):1934-42. PubMed ID: 17406951 [TBL] [Abstract][Full Text] [Related]
18. Molecular risk prediction in cutaneous melanoma: A meta-analysis of the 31-gene expression profile prognostic test in 1,479 patients. Greenhaw BN; Covington KR; Kurley SJ; Yeniay Y; Cao NA; Plasseraud KM; Cook RW; Hsueh EC; Gastman BR; Wei ML J Am Acad Dermatol; 2020 Sep; 83(3):745-753. PubMed ID: 32229276 [TBL] [Abstract][Full Text] [Related]
19. Sentinel lymph node biopsy in malignant melanoma of the head and neck. Rahimi-Nedjat RK; Al-Nawas B; Tuettenberg A; Sagheb K; Grabbe S; Walter C J Craniomaxillofac Surg; 2018 Jun; 46(6):1027-1031. PubMed ID: 29735384 [TBL] [Abstract][Full Text] [Related]
20. Methods of detection of first recurrence in patients with stage I/II primary cutaneous melanoma after sentinel lymph node biopsy. Moore Dalal K; Zhou Q; Panageas KS; Brady MS; Jaques DP; Coit DG Ann Surg Oncol; 2008 Aug; 15(8):2206-14. PubMed ID: 18512102 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]